Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

11 treatments under study, led by Laboratory Biomarker Analysis

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 1 (2)
Phase 2 (1)

Trial Status

Completed2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05735912Not ApplicableActive Not RecruitingPrimary

EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)

NCT00454363Phase 2Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT02831179Phase 1Withdrawn

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

NCT01204476Phase 1Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Showing all 4 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis3
  • Pharmacological Study3
  • Temozolomide1
  • Pazopanib Hydrochloride1
  • Octreotide Acetate1

Active Sponsors

  • National Cancer Institute (NCI)3
  • Azienda Ospedaliera Universitaria Integrata Verona1
  • Vanderbilt-Ingram Cancer Center1

Top Investigators

Related Conditions

  • Somatostatinproducing Neuroendocrine Tumor3
  • Pancreatic Glucagonoma3
  • Metastatic Digestive System Neuroendocrine Tumor G12
  • Recurrent Pancreatic Neuroendocrine Carcinoma2
  • Lung Carcinoid Tumor2

Activity Timeline